Lace M. Riggs, M.A.
GRADUATE STUDENT PROGRAM IN NEUROSCIENCE
|
Education
M.A. in Experimental Psychology, California State University, San Bernardino, CA B.A. in Biological Psychology, California State University, San Bernardino, CA Current Projects Examining the neurophysiological mechanisms of rapid antidepressant efficacy. Other Research Interests Neurodevelopment, addiction, epigenetics, research ethics, health disparities, diversity. Contact Information Email: lacemriggs[at]umaryland.edu Phone: (410) 706-6799 |
Description
I earned a B.A. in Biological Psychology and an M.A. in Experimental Psychology from California State University. There, I studied risk factors associated with enhanced susceptibility to adolescent depression, as well as the enduring neurobehavioral adaptations that result from antidepressant treatment during this period in development. I later became interested in synaptic plasticity as (1) a fundamental mechanism underlying long-lasting changes in behavior, (2) as a constituent in the pathophysiology of many neuropsychiatric conditions, and (3) as a means to establish a therapeutically-beneficial change in the efficacy of synaptic transmission. This led me to join the Gould Lab at the University of Maryland School of Medicine, where I am earning a Ph.D. in Neuroscience in the Graduate Program in Life Sciences. I am currently using behavioral, electrophysiological, and photometric approaches to investigate the mechanisms underlying the rapid antidepressant actions of the ketamine metabolite, (2R,6R)-hydroxynorketamine. The long-term objective of my career is to use multidisciplinary approaches to advance novel therapeutic development for treatment-resistant psychiatric conditions.
I earned a B.A. in Biological Psychology and an M.A. in Experimental Psychology from California State University. There, I studied risk factors associated with enhanced susceptibility to adolescent depression, as well as the enduring neurobehavioral adaptations that result from antidepressant treatment during this period in development. I later became interested in synaptic plasticity as (1) a fundamental mechanism underlying long-lasting changes in behavior, (2) as a constituent in the pathophysiology of many neuropsychiatric conditions, and (3) as a means to establish a therapeutically-beneficial change in the efficacy of synaptic transmission. This led me to join the Gould Lab at the University of Maryland School of Medicine, where I am earning a Ph.D. in Neuroscience in the Graduate Program in Life Sciences. I am currently using behavioral, electrophysiological, and photometric approaches to investigate the mechanisms underlying the rapid antidepressant actions of the ketamine metabolite, (2R,6R)-hydroxynorketamine. The long-term objective of my career is to use multidisciplinary approaches to advance novel therapeutic development for treatment-resistant psychiatric conditions.
funding
Current
T32 GM008181, Training Program in Integrative Membrane Biology, National Institutes of Health, National Institute of General Medical Sciences, University of Maryland School of Medicine, Baltimore MD.
Previous
T32 NS063391, Student of Merit, Training Program in Neuroscience, National Institutes of Health, National Institute of Neurological Disorders and Stroke, University of Maryland School of Medicine, Baltimore MD.
R25 GM055036, Meyerhoff Graduate Fellow, National Institutes of Health, Initiative for Maximizing Student Development, University of Maryland School of Medicine, Baltimore MD.
R24 DA033877, Predoctoral Fellow, National Institute on Drug Abuse, Diversity Promoting Institutions Drug Abuse Research Program, California State University, San Bernardino CA.
T32 GM008181, Training Program in Integrative Membrane Biology, National Institutes of Health, National Institute of General Medical Sciences, University of Maryland School of Medicine, Baltimore MD.
Previous
T32 NS063391, Student of Merit, Training Program in Neuroscience, National Institutes of Health, National Institute of Neurological Disorders and Stroke, University of Maryland School of Medicine, Baltimore MD.
R25 GM055036, Meyerhoff Graduate Fellow, National Institutes of Health, Initiative for Maximizing Student Development, University of Maryland School of Medicine, Baltimore MD.
R24 DA033877, Predoctoral Fellow, National Institute on Drug Abuse, Diversity Promoting Institutions Drug Abuse Research Program, California State University, San Bernardino CA.
selected publications
Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD (2019). (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology, PMID: 31216563.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018). Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews, 70(3):621-660. PMID: 29945898.
For full list, please visit:
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018). Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews, 70(3):621-660. PMID: 29945898.
For full list, please visit:
|
|
